Anika Therapeutics, Inc.
General ticker "ANIK" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $165.8M (TTM average)
Anika Therapeutics, Inc. follows the US Stock Market performance with the rate: 47.9%.
Estimated limits based on current volatility of 2.1%: low 20.09$, high 20.97$
Factors to consider:
- Total employees count: 235 (-18.4%) as of 2025
- US accounted for 62.1% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Customer concentration, Strategic risks and growth management, Labor/talent shortage/retention, Manufacturing disruptions, Regulatory and compliance
- Current price 10.5% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.83$, 18.09$]
- 2026-12-31 to 2027-12-31 estimated range: [12.37$, 20.10$]
Financial Metrics affecting the ANIK estimates:
- Positive: with PPE of 59.4 at the end of fiscal year the price was neutral
- Positive: -13.52 < Operating profit margin, % of -8.92
- Positive: 6.77 < Operating cash flow per share per price, % of 8.21
- Negative: -3.92 < Inventory ratio change, % of -2.29
- Negative: negative Net income
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Negative: 0.47 < Industry inventory ratio change (median), % of 0.70
- Negative: negative Industry operating cash flow (median)
Short-term ANIK quotes
Long-term ANIK plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $120.79MM | $119.91MM | $112.82MM |
| Operating Expenses | $119.95MM | $125.01MM | $123.87MM |
| Operating Income | $0.84MM | $-5.10MM | $-11.05MM |
| Non-Operating Income | $2.31MM | $2.34MM | $1.74MM |
| R&D Expense | $21.76MM | $25.54MM | $25.77MM |
| Income(Loss) | $3.16MM | $-2.76MM | $-9.31MM |
| Taxes | $6.59MM | $6.06MM | $0.67MM |
| Other Income(Loss) | $-79.23MM | $-47.56MM | $-0.90MM |
| Net Income(Loss)* | $-82.67MM | $-56.38MM | $-10.88MM |
| Stockholders Equity | $212.26MM | $153.99MM | $143.47MM |
| Inventory | $24.43MM | $23.81MM | $18.79MM |
| Assets | $270.63MM | $202.74MM | $190.27MM |
| Operating Cash Flow | $-1.79MM | $5.40MM | $11.19MM |
| Capital expenditure | $5.43MM | $7.73MM | $6.83MM |
| Investing Cash Flow | $-5.43MM | $-8.33MM | $-0.40MM |
| Financing Cash Flow | $-6.32MM | $-12.73MM | $-10.55MM |
| Earnings Per Share** | $-5.64 | $-3.83 | $-0.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.